To investigate the clinical utility of molecular breast imaging (MBI) in patients with proven invasive breast cancer scheduled for breast-conserving surgery (BCS).
Following approval by the institutional review board and written informed consent, records of patients with newly diagnosed breast cancer scheduled for BCS who had undergone MBI for local staging in the period from March 2012 till December 2014 were retrospectively reviewed.
A total of 287 women (aged 30–88 years) were evaluated. MBI showed T stage migration in 26 patients (9%), with frequent detection of in situ carcinoma around the tumor. Surgical management was adjusted in 14 of these patients (54%). In 17 of 287 patients (6%), MBI revealed 21 proven additional lesions in the ipsilateral, contralateral breast or both. In 18 of these additional foci (86%), detected in 15 patients, malignancy was found. Thirteen of these 15 patients had ipsilateral cancer and 2 patients bilateral malignancy. In total, MBI revealed a larger tumor extent, additional tumor foci or both in 40 patients (14%), leading to treatment adjustment in 25 patients (9%).
MBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography and ultrasound may lead to better selection of patients who could benefit from BCS.
Netherlands Cancer Registry. http://www.cijfersoverkanker.nl. Accessed 02 Nov 2016
International Agency for Research on Cancer (IARC) and World Health Organization (WHO). GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 03 Jan 2018
Gradishar WJ, Anderson BO, Balassanian R et al (2016) Breast cancer version 2.2016, NCCN Clinical Practice Guidelines in Oncology. http://www.nccn.org/professionals/physician_gls/pdf/breat.pdf. Accessed 02 Nov 2016
Brem RF, Schoonjans JM, Kieper DA, Majewski S, Goodman S, Civelek C (2002) High-resolution scintimammography: a pilot study. J Nucl Med 43(7):909–915 PubMed
Hruska CB, Weinmann AL, Tello Skjerseth CM, Wagenaar EM, Conners AL, Tortorelli CL, Maxwell RW, Rhodes DJ, O’Connor MK (2012) Proof of concept for low-dose molecular breast imaging with a dual-head CZT gamma camera. Part II. Evaluation in patients. Med Phys 39(6):3476–3483 CrossRefPubMedPubMedCentral
Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG (1990) Uptake of the cation hexakis(2-methoxyisobutylisonitrile)-technetium-99 m by human carcinoma cell lines in vitro. Cancer Res 50(7):2198–2202 PubMed
Kieper DA, Welch BL, Fairchild LH, inventors; Dilon Technologies, Inc., assignee (2012) Gamma guided stereotactic localization system. US Patent US8249693. 21 Aug 2012
- The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery
Renato A. Valdés Olmos
Lotta G. A. J. van Berkel
Peter A. Neijenhuis
Lidy M. H. Wijers
Lioe-Fee de Geus-Oei
Lenka M. Pereira Arias-Bouda
- Springer US
Neu im Fachgebiet Onkologie
Mail Icon II